The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the tyrosine kinase inhibitor Inlyta (axitinib) in the first-line treatment of advanced renal...
Latest articles
Content en communicatie: dé trends & tips voor de tweede helft van 2019
We zijn natuurlijk al flink op weg in 2019, maar ‘na de zomer’ voelt toch altijd een beetje als de tweede helft van het jaar. Heb jij al scherp waarop jij je deze laatste maanden gaat focussen? Of is alles weggeëbd...
Novartis phase III ASCLEPIOS I & II studies of ofatumumab versus Aubagio to treat relapsing forms MS meets primary endpoints
Novartis announced positive results for ofatumumab (OMB157) from the phase III ASCLEPIOS I and II studies. In both head─to─head studies, ofatumumab demonstrated superiority over Aubagio (teriflunomide) in patients
AstraZeneca presents strong Phase 3 Brilinta data for reducing CV risk
AstraZeneca has unveiled new positive Phase 3 data on the efficacy of Brilinta (ticagrelor) in combination with aspirin, showing that the therapy reduced the relative risk for the composite of cardiovascular (CV) death...
Roche’s Tecentriq combo becomes first EU-approved immunotherapy for triple-negative breast cancer
Roche has announced the approval of Tecentriq (atezolizumab), in combination with Celgene’s chemotherapy drug Abraxane (nab paclitaxel), by the European Medicines Agency in the treatment of PD-L1-positive, unresectable...
5 Actions Backed by Research to Improve Your Content Marketing
Now is a great time to evaluate your content marketing. If your program isn’t yet where you want it to be, now’s the time to start making some tweaks. Here’s a refresher of CMI’s 2019 research and resources to help...
